Literature DB >> 15725090

Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens.

Anne-Sophie Michallet1, Sabine Fürst, Quoc Hung Le, Valérie Dubois, Aline Praire, Franck Nicolini, Xavier Thomas, Hanadi Rafii, Lucette Gebuhrer, Mauricette Michallet.   

Abstract

This retrospective study aimed to analyse the impact on overall survival (OS) and event-free survival (EFS) of chimaerism status and kinetics following allogeneic conventional and reduced-intensity conditioning haematopoietic stem cell transplantation, and to compare this with the impact of other well-known factors. We investigated the chimaerism status of 187 patients [84 females, 103 males; median age 39.5 years (range, 17-62 years)]. After transplantation, 121 patients (65%) presented full donor chimaerism (FDC) and 63 (34%) mixed chimaerism (MC). For MC, we divided the population into patients who presented regressive mixed chimaerism (RMC) (21 patients: 11%), stable mixed chimaerism (SMC) (20 patients: 11%) and progressive mixed chimaerism (PMC) (22 patients: 12%). At last follow-up, 71 patients were alive and 116 had died (48% from disease progression and 52% from transplant-related causes). With a mean follow-up of 39.4 and 34.8 months, the 5-year probabilities of OS and EFS for the total group were, respectively, 55% and 43%: 69.5% and 61% for FDC, 35.4% and 25% for RMC, 42.6% and 28.6% for SMC, and 21% and 10.4% for PMC (P < 0.0001 and P < 0.0001). Multivariate analysis only showed a significant impact of chimaerism status on OS, as well as acute and chronic graft-versus-host disease on EFS, with a trend for conditioning regimen.

Entities:  

Mesh:

Year:  2005        PMID: 15725090     DOI: 10.1111/j.1365-2141.2005.05372.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.

Authors:  J Pidala; J Kim; C Anasetti; M A Kharfan-Dabaja; T Field; J Perkins; E Ayala; L Perez; H Fernandez
Journal:  Bone Marrow Transplant       Date:  2010-08-16       Impact factor: 5.483

Review 2.  Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

Authors:  S Abdul Wahid Fadilah; Md Pazil Aqilah
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

3.  Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Ri-Young Goh; Sung-Hyun Kim; Jin-Yeong Han
Journal:  Korean J Hematol       Date:  2011-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.